Dec 12, 2019
European Commission Approves EVENITY® (romosozumab) For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
Jun 28, 2019
Amgen and UCB Provide Regulatory Update on Status of EVENITY(TM) (romosozumab) in the EU
Apr 18, 2019
Osteoporosis Drugs Market Insights Report, 2019 - Availability of Reimbursement Programs for Patients with Osteoporosis Will Drive Market Growth
Apr 09, 2019
FDA Approves EVENITY(TM) (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
Jun 08, 2018
European Commission Approves Prolia® (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
May 21, 2018
FDA Approves Prolia® (Denosumab) For Glucocorticoid-Induced Osteoporosis
May 07, 2018
HSS Researchers Launch Study to Measure Bone Effects of New Rheumatologic Agent
Apr 27, 2018
Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia® (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis
Apr 03, 2018
European Commission Approves Expanded Indication For Amgen's XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
Feb 23, 2018
Amgen Receives Positive Opinion Expanding Use Of XGEVA® (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe
Jan 05, 2018
FDA Approves XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
Jun 19, 2017
FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA® (denosumab) To Include Multiple Myeloma Patients
Jun 04, 2017
Amgen Presents New Data From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma At ASCO 2017